No Data
Analysts' Revenue Estimates For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher
What Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) P/S Is Not Telling You
A Closer Look at 4 Analyst Recommendations For Recursion Pharmaceuticals
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $11
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target
Buy Rating for Recursion Pharmaceuticals Amid Strategic Merger and Innovative Drug Development
No Data
No Data
